Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Empagliflozin Use Is Associated With Lower Risk of All‐Cause Mortality, Hospitalization for Heart Failure, and End‐Stage Renal Disease Compared to DPP‐4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request